keyword
MENU ▼
Read by QxMD icon Read
search

chemoimmunotherapy

keyword
https://www.readbyqxmd.com/read/29331216/chemoimmunotherapy-in-metastatic-urothelial-carcinoma
#1
EDITORIAL
Daniel M Geynisman, Phillip H Abbosh, Elizabeth R Plimack, Matthew Zibelman
No abstract text is available yet for this article.
January 10, 2018: European Urology
https://www.readbyqxmd.com/read/29317997/experience-with-ibrutinib-for-first-line-use-in-patients-with-chronic-lymphocytic-leukemia
#2
REVIEW
Gilad Itchaki, Jennifer R Brown
Ibrutinib is the first in-class, orally administered, Bruton's tyrosine kinase (BTK) inhibitor that abrogates the critical signaling downstream of the B-cell receptor (BCR). This signaling is required for B-cell survival, proliferation and interaction with the microenvironment. Ibrutinib proved active in preclinical models of lymphoproliferative diseases and achieved impressive response rates in heavily pretreated relapsed and refractory (R/R) patients with chronic lymphocytic leukemia (CLL). Ibrutinib prolonged survival compared to standard therapy and mitigated the effect of most poor prognostic factors in CLL, thus becoming the main therapeutic option in high-risk populations...
January 2018: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/29311032/two-months-of-therapy-a-case-of-pathologic-complete-response-to-chemoimmunotherapy-in-a-patient-with-metastatic-colorectal-cancer
#3
Samantha Armstrong, Hayma Al-Ghawi, Paul Helft, Michael G House, Aaron J Spittler, Howard H Wu, Safi Shahda
No abstract text is available yet for this article.
December 13, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29308329/assessment-of-neuronal-autoantibodies-in-patients-with-small-cell-lung-cancer-treated-with-chemotherapy-with-or-without-ipilimumab
#4
M Hardy-Werbin, O Arpí, A Taus, P Rocha, D Joseph-Pietras, L Nolan, S Danson, R Griffiths, M Lopez-Botet, A Rovira, J Albanell, C H Ottensmeier, E Arriola
Small-cell lung cancer (SCLC) is often associated with paraneoplastic syndromes. To assess the role of anti-neuronal autoantibodies (NAAs) as biomarkers of treatment outcome, we assessed NAAs in serial samples from SCLC patients treated with chemoimmunotherapy compared to chemotherapy alone. We evaluated 2 cohorts: in cohort 1 (C1), 47 patients received standard platinum/etoposide, and in cohort 2 (C2), 38 patients received ipilimumab, carboplatin and etoposide. Serum samples at baseline and subsequent time points were analyzed for the presence of NAAs...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29296893/early-progression-of-disease-as-a-predictor-of-survival-in-chronic-lymphocytic-leukemia
#5
Inhye E Ahn, Charles M Farber, Matthew S Davids, David L Grinblatt, Neil E Kay, Nicole Lamanna, Anthony Mato, Chadi Nabhan, Pavel Kiselev, Arlene S Swern, E Dawn Flick, Kristen Sullivan, Jeff P Sharman, Christopher R Flowers
Chemoimmunotherapy for chronic lymphocytic leukemia (CLL) promotes clonal evolution of aggressive clones, which in some patients may lead to early progression of disease (POD). We studied the prognostic value of early POD in a cohort of patients with CLL enrolled between 2010 and 2014 in the Connect CLL Registry. Overall, 829 eligible patients receiving first-line therapy were categorized into 3 groups: early POD (progression <2 years after treatment initiation), late POD (progression ≥2 years after treatment initiation), and no POD as of 1 May 2017...
November 28, 2017: Blood Advances
https://www.readbyqxmd.com/read/29275118/rituximab-maintenance-versus-observation-following-abbreviated-induction-with-chemoimmunotherapy-in-elderly-patients-with-previously-untreated-chronic-lymphocytic-leukaemia-cll-2007-sa-an-open-label-randomised-phase-3-study
#6
Caroline Dartigeas, Eric Van Den Neste, Julie Léger, Hervé Maisonneuve, Christian Berthou, Marie-Sarah Dilhuydy, Sophie De Guibert, Stéphane Leprêtre, Marie C Béné, Florence Nguyen-Khac, Rémi Letestu, Florence Cymbalista, Philippe Rodon, Thérèse Aurran-Schleinitz, Jean-Pierre Vilque, Olivier Tournilhac, Béatrice Mahé, Kamel Laribi, Anne-Sophie Michallet, Alain Delmer, Pierre Feugier, Vincent Lévy, Roselyne Delépine, Philippe Colombat, Véronique Leblond
BACKGROUND: Most patients with chronic lymphocytic leukaemia relapse after initial therapy combining chemotherapy with rituximab. We assessed the efficacy and safety of rituximab maintenance treatment versus observation for elderly patients in remission after front-line abbreviated induction by fludarabine, cyclophosphamide, and rituximab (FCR). METHODS: This randomised, open-label, multicentre phase 3 trial at 89 centres in France enrolled treatment-naive and fit patients aged 65 years or older with chronic lymphocytic leukaemia without del(17p)...
December 20, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29250930/management-of-high-risk-chronic-lymphocytic-leukaemia-cll-patients-in-australia
#7
REVIEW
Bryone J Kuss, Constantine S Tam
BACKGROUND: Chronic lymphocytic leukaemia (CLL) frequently responds to chemoimmunotherapy combining cytotoxic chemotherapy and monoclonal antibodies. However, CLL is associated with significant genetic heterogeneity, and some high-risk forms are known to be chemo-resistant and associated with early relapse. AIMS: To review the current treatment paradigm of patients with high-risk disease, in particular those with del(17p) and TP53 variants. RESULTS: A 'watch and wait' approach is recommended for all patients who are asymptomatic...
December 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/29243946/ibrutinib-and-its-use-in-the-treatment-of-chronic-lymphocytic-leukemia
#8
Anna Maria Frustaci, Alessandra Tedeschi, Marina Deodato, Maddalena Mazzucchelli, Roberto Cairoli, Marco Montillo
Ibrutinib represents a revolution in chronic lymphocytic leukemia treatment scenario providing results never seen before and offering an effective therapy even in high-risk patients with really poor outcome after chemoimmunotherapy. Thanks to longer updates, on one hand, ibrutinib has confirmed its efficacy continuing to show clinical benefits over time; on the other hand, resistance mechanisms are slowly emerging. Moreover, clinicians should be aware of ibrutinib-related side effects, paying attention to screen patients that could benefit more from the drug and try to prevent adverse events...
December 15, 2017: Future Oncology
https://www.readbyqxmd.com/read/29242506/micrornas-regulate-key-cell-survival-pathways-and-mediate-chemosensitivity-during-progression-of-diffuse-large-b-cell-lymphoma
#9
Suvi-Katri Leivonen, Katherine Icay, Kirsi Jäntti, Ilari Siren, Chengyu Liu, Amjad Alkodsi, Alejandra Cervera, Maja Ludvigsen, Stephen Jacques Hamilton-Dutoit, Francesco d'Amore, Marja-Liisa Karjalainen-Lindsberg, Jan Delabie, Harald Holte, Rainer Lehtonen, Sampsa Hautaniemi, Sirpa Leppä
Despite better therapeutic options and improved survival of diffuse large B-cell lymphoma (DLBCL), 30-40% of the patients experience relapse or have primary refractory disease with a dismal prognosis. To identify biological correlates for treatment resistance, we profiled microRNAs (miRNAs) of matched primary and relapsed DLBCL by next-generation sequencing. Altogether 492 miRNAs were expressed in the DLBCL samples. Thirteen miRNAs showed significant differential expression between primary and relapse specimen pairs...
December 15, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29242111/autologous-transplantation-in-follicular-lymphoma-with-early-therapy-failure-a-nlcs-and-cibmtr-analysis
#10
Carla Casulo, Jonathan W Friedberg, Kwang Woo Ahn, Christopher Flowers, Alyssa DiGilio, Sonali M Smith, Sairah Ahmed, David Inwards, Mahmoud Aljurf, Andy I Chen, Hannah Choe, Jonathon Cohen, Edward Copelan, Umar Farooq, Timothy S Fenske, Cesar Freytes, Sameh Gaballa, Siddhartha Ganguly, Yogesh Jethava, Rammurti T Kamble, Vaishalee P Kenkre, Hillard Lazarus, Aleksandr Lazaryan, Richard F Olsson, Andrew R Rezvani, David Rizzieri, Sachiko Seo, Gunjan L Shah, Nina Shah, Melham Solh, Anna Sureda, Basem William, Aaron Cumpston, Andrew D Zelenetz, Brian K Link, Mehdi Hamadani
Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within two years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup.ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within two years of frontline chemoimmunotherapy...
December 11, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29232542/allogeneic-transplantation-for-follicular-lymphoma-does-one-size-fit-all
#11
Mehdi Hamadani, Mary M Horowitz
Follicular lymphoma (FL) exhibits striking biologic and clinical heterogeneity. Patients with newly diagnosed asymptomatic or low-bulk disease may be observed or managed with immunotherapies alone. Chemoimmunotherapy is considered a standard treatment for patients with advanced, symptomatic disease. In patients with FL who achieve at least a partial remission after first-line chemoimmunotherapy, autologous (auto-) hematopoietic cell transplantation (HCT) consolidation is not recommended; however, most patients with FL experience disease relapse after frontline therapies, with the experience of therapy failure within 2 years of first-line treatments predicting poor survival...
December 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29222670/venetoclax-for-treating-chronic-lymphocytic-leukaemia-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#12
REVIEW
Hema Mistry, Chidozie Nduka, Martin Connock, Jill Colquitt, Theodoros Mantopoulos, Emma Loveman, Renata Walewska, James Mason
Venetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (NICE) invited AbbVie, the manufacturer, to submit evidence on the use of venetoclax, within its licensed indication. The Evidence Review Group (ERG), Warwick Evidence, was asked to provide an independent and critical review of the submitted evidence. Evidence came from three single-arm trials in CLL patients with or without 17p deletion [del(17p])/TP53 chromosomal abnormalities...
December 8, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29222277/how-should-we-sequence-and-combine-novel-therapies-in-cll
#13
REVIEW
Matthew S Davids
With the recent approval of several effective and well-tolerated novel agents (NAs), including ibrutinib, idelalisib, venetoclax, and obinutuzumab, patients with chronic lymphocytic leukemia (CLL) have more therapeutic options than ever before. The availability of these agents is both an important advance for patients but also a challenge for practicing hematologist/oncologists to learn how best to sequence NAs, both with respect to chemoimmunotherapy (CIT) and to other NAs. The sequencing of NAs in clinical practice should be guided both by an individual patient's prognostic markers, such as FISH and immunoglobulin heavy chain variable region (IGHV)-mutation status, as well as the patient's medical comorbidities and goals of care...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29222275/the-mutational-landscape-of-chronic-lymphocytic-leukemia-and-its-impact-on-prognosis-and-treatment
#14
REVIEW
Gianluca Gaidano, Davide Rossi
The typical genome of chronic lymphocytic leukemia (CLL) carries ∼2000 molecular lesions. Few mutations recur across patients at a frequency >5%, whereas a large number of biologically and clinically uncharacterized genes are mutated at lower frequency. Approximately 80% of CLL patients carry at least 1 of 4 common chromosomal alterations, namely deletion 13q14, deletion 11q22-23, deletion 17p12, and trisomy 12. Knowledge of the CLL genome has translated into the availability of molecular biomarkers for prognosis and treatment prediction...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29209567/dendritic-cells-pulsed-with-tumor-cells-killed-by-high-hydrostatic-pressure-inhibit-prostate-tumor-growth-in-tramp-mice
#15
Romana Mikyskova, Marie Indrova, Ivan Stepanek, Ivan Kanchev, Jana Bieblova, Sarka Vosahlikova, Irena Moserova, Iva Truxova, Jitka Fucikova, Jirina Bartunkova, Radek Spisek, Radislav Sedlacek, Milan Reinis
Dendritic cell (DC)-based vaccines pulsed with high hydrostatic pressure (HHP)-inactivated tumor cells have recently been shown to be a promising tool for prostate cancer chemoimmunotherapy. In this study, DC-based vaccines, both pulsed and unpulsed, were as effective as docetaxel (DTX) in reducing prostate tumors in the orthotopic transgenic adenocarcinoma of the mouse prostate (TRAMP) model. However, we did not observe any additive or synergic effects of chemoimmunotherapy on the tumor growth, while only the combination of DTX and pulsed dendritic cells resulted in significantly lower proliferation detected by Ki67 staining in histological samples...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29195615/pet-ct-for-lymphoma-post-therapy-response-assessment-in-hodgkin-lymphoma-and-diffuse-large-b-cell-lymphoma
#16
REVIEW
Carsten Kobe, Markus Dietlein, Dirk Hellwig
Over the course of many decades, combined chemotherapy and radiotherapy adapted to the stage of disease have become the optimal and standard treatment for Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma. Besides achieving optimized cure rates of the underlying disease, reduction of toxicity has become a major goal. Since the introduction of FDG-PET for the staging and restaging of patients with lymphoma, a high predictive value of F-18-FDG-PET in response assessment has been observed. Several PET-response-guided therapy regimens have already been established, and even more PET-adapted study designs are being tested in large study groups...
January 2018: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/29193006/a-single-institution-retrospective-cohort-study-of-first-line-r-epoch-chemoimmunotherapy-for-richter-syndrome-demonstrating-complex-chronic-lymphocytic-leukaemia-karyotype-as-an-adverse-prognostic-factor
#17
Kerry A Rogers, Ying Huang, Amy S Ruppert, Galena Salem, Deborah M Stephens, Nyla A Heerema, Leslie A Andritsos, Farrukh T Awan, John C Byrd, Joseph M Flynn, Kami J Maddocks, Jeffrey A Jones
Richter Syndrome, an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia (CLL), has a generally poor prognosis and anthracycline-based chemoimmunotherapy regimens designed to treat de novo diffuse large B-cell lymphoma achieve modest clinical benefit. R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) has demonstrated greater activity against aggressive B-cell histologies but has not been studied in Richter Syndrome. We conducted a retrospective cohort study of 46 Richter Syndrome patients treated with first-line R-EPOCH at our institution between 1 January 2006 and 31 May 2014...
November 28, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/29180934/long-term-survival-in-a-patient-with-unresectable-liver-metastases-from-uveal-melanoma-treated-with-transarterial-chemoembolization-with-irinotecan-eluting-beads-case-report-and-review-of-literature
#18
Katarzyna Stanisławska, Honorata Stadnik, Mikołaj Nawrocki, Katarzyna Ramlau-Piątek, Robert Juszkat, Michał Drews
Introduction: Treatment of unresectable liver metastases (LM) from uveal melanoma (UM) remains a major clinical challenge. Systemic chemotherapy and chemoimmunotherapy regimens extrapolated from cutaneous melanoma are considered to be ineffective in therapy of metastases from uveal melanoma. Studies suggest that the progression of hepatic metastases rather than the primary tumor or metastases in other organs determines survival. Case report: We report a case of transarterial chemoembolization of 57-year-old man diagnosed with unresectable liver metastases from uveal melanoma with irinotecan eluting beads...
2017: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/29168471/complete-response-of-metastatic-gastric-cancer-to-chemoimmunotherapy
#19
Kenji Ina, Ryuichi Furuta
No abstract text is available yet for this article.
July 2017: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/29151814/de-novo-acute-lymphoblastic-leukemia-like-disease-of-high-grade-b-cell-lymphoma-with-myc-and-bcl2-and-or-bcl6-rearrangements-a-case-report-and-literature-review
#20
Akiko Uchida, Yasushi Isobe, Yu Uemura, Yuji Nishio, Hirotaka Sakai, Masayuki Kato, Kaori Otsubo, Masahiro Hoshikawa, Masayuki Takagi, Ikuo Miura
Background: B-cell lymphomas harboring the 8q24/MYC plus 18q21/BCL2 translocations are now referred to as high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-MBR). Although HGBL-MBR is frequently found in cases with diffuse large B-cell lymphoma or Burkitt lymphoma-like B-cell lymphoma, acute lymphoblastic leukemia (ALL)-like disease of HGBL-MBR (AL-HGBL-MBR) has been reported incidentally. Case presentation: A 69-year-old Japanese woman developed remittent fever and increasing systemic bone pain...
2017: BMC Clinical Pathology
keyword
keyword
28305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"